Evidence map›Paper›PMID 27061794›Full record

Observational studyJournal of thrombosis and haemostasis : JTH2016

The association of statin therapy with the risk of recurrent venous thrombosis.

N L Smith, L B Harrington, M Blondon, K L Wiggins, J S Floyd, C M Sitlani, B McKnight, E B Larson, F R Rosendaal, S R Heckbert and 1 more

Open access · greenAbstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Journal of thrombosis and haemostasis : JTH, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Incident thrombus location and predicting risk of recurrent venous thromboembolism.Research and practice in thrombosis and haemostasis · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Statins as a preventative therapy for venous thromboembolism.Cardiovascular diagnosis and therapy · 2017
    Review
  11. Article
  12. Article
  13. A thrombotic storm.Internal and emergency medicine · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 3 countries.

N L SmithDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
L B HarringtonDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
M BlondonDivision of Angiology and Haemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
K L WigginsDepartment of Medicine, University of Washington, Seattle, WA, USA.
J S FloydDepartment of Medicine, University of Washington, Seattle, WA, USA.
C M SitlaniDepartment of Medicine, University of Washington, Seattle, WA, USA.
B McKnightDepartment of Biostatistics, University of Washington, Seattle, WA, USA.
E B LarsonGroup Health Research Institute, Group Health Cooperative, Seattle, WA, USA.
F R RosendaalDepartments of Clinical Epidemiology and of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, the Netherlands.
S R HeckbertDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
B M PsatyDepartment of Epidemiology, University of Washington, Seattle, WA, USA.
University of Washington · USGroup Health Cooperative · USLeiden University Medical Center · NLUniversity Hospital of Geneva · CHVA Office of Research and Development · US

Funding

Genome-wide case-only study of antihypertensive drug-gene interactionsR01HL085251 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2007 to 2010
$7.2M
Estrogens and pharmacogenetic risks of venous thrombosis in postmenopausal womenR01HL073410 · NHLBI · UNIVERSITY OF WASHINGTON · PI SMITH, NICHOLAS L · 2004 to 2012
$4.8M
Atrial Fibrillation: Incidence, Risk Factors, and GeneticsR01HL068986 · NHLBI · UNIVERSITY OF WASHINGTON · PI HECKBERT, SUSAN R · 2002 to 2010
$3.5M
CALCIUM-CHANNEL BLOCKERS AND PRIMARY PREVENTION OF CHDR01HL043201 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 1991 to 2004
$3.0M
Pharmacologic and pharmacogenetic associations with recurrent venous thrombosisR01HL095080 · NHLBI · UNIVERSITY OF WASHINGTON · PI SMITH, NICHOLAS L · 2008 to 2012
$2.9M
Pharmacogenetics and Cardiovascular EventsR01HL074745 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 2003 to 2006
$2.8M
MUTATIONS, HORMONE THERAPY, AND VENOUS THROMBOEMBOLISMR01HL060739 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE M · 1998 to 2001
$1.1M
NHLBI NIH HHS R01 HL043201NHLBI NIH HHS R01 HL060739NHLBI NIH HHS R01 HL068986NHLBI NIH HHS R01 HL073410NHLBI NIH HHS R01 HL074745NHLBI NIH HHS R01 HL085251NHLBI NIH HHS R01 HL095080
6 · The paper itself

Abstract

unlabelledEssentials A lowered risk of recurrent venous thrombosis (VT) with statin treatment is controversial. Among observational inception cohort of 2,798 adults with incident VT, 457 had recurrent VT. Time-to-event models with time-varying statin use and adjustment for potential confounders was used for analysis. Compared to nonuse, current statin use was associated with 26% lower risk of recurrent VT. Click to hear Prof. Büller's perspective on Anticoagulant Therapy in the Treatment of Venous Thromboembolism SUMMARY: Background Meta-analyses of randomized controlled trials suggest that treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) lowers the risk of incident venous thrombosis (VT), particularly among those without prevalent clinical cardiovascular disease (CVD). Whether this is true for the prevention of recurrent VT is debated. We used an observational inception cohort to estimate the association of current statin use with the risk of recurrent VT. Methods and Results The study setting was a large healthcare organization with detailed medical record and pharmacy information at cohort entry and throughout follow-up. We followed 2798 subjects 18-89 years of age who experienced a validated incident VT between January 1, 2002, and December 31, 2010, for a first recurrent VT, validated by medical record review. During follow-up, 457 (16%) developed a first recurrent VT. In time-to-event models incorporating time-varying statin use and adjusting for potential confounders, current statin use was associated with a 26% lower risk of recurrent VT: hazard ratio 0.74, 95% confidence interval 0.59-0.94. Among cohort members free of CVD (n = 2134), current statin use was also associated with a lower risk (38%) of recurrent VT: hazard ratio 0.62, 95% confidence interval 0.45-0.85. We found similar results when restricting to new users of statins and in subgroups of different statin types and doses. Conclusions In a population-based cohort of subjects who had experienced an incident VT, statin use, compared with nonuse, was associated with a clinically relevant lower risk of recurrent VT. These findings suggest a potential secondary benefit of statins among patients who have experienced an incident VT.

Indexed as

Administration, OralAdolescentAdultAgedAged, 80 and overAnticoagulantsCardiovascular DiseasesContraceptives, OralEstrogensFemaleFollow-Up StudiesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPrevalenceAnticoagulantsContraceptives, OralEstrogensHydroxymethylglutaryl-CoA Reductase Inhibitorscohort studieshydroxymethylglutaryl-CoA reductase inhibitorspharmacoepidemiologyrecurrencevenous thrombosis

Identifiers

PMID27061794
PMCPMC4966556
OpenAlexW2313835304

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.